Product nameAnti-PKC alpha + beta + gamma antibody [EPR16898] (HRP)
See all PKC alpha + beta + gamma primary antibodies
DescriptionRabbit monoclonal [EPR16898] to PKC alpha + beta + gamma (HRP)
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Rat, Human
Predicted to work with: Mouse
Recombinant fragment within Human PKC alpha + beta + gamma aa 300-500. The exact sequence is proprietary. Also SwissProt IDs: P17252 = Protein kinase C alpha type. P05129 = Protein kinase C gamma type.
Database link: P05771
- WB: Human fetal brain and rat brain tissue lysates.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. Store In the Dark.
Storage bufferpH: 7.4
Preservative: 0.1% Proclin
Constituents: 1% BSA, 30% Glycerol, PBS
Concentration information loading...
PurityProtein A purified
- Anti-PKC antibody [EPR16898] (ab179522)
- Anti-PKC alpha + beta + gamma antibody [EPR16898] (Alexa Fluor® 647) (ab205478)
- Anti-PKC alpha + beta + gamma antibody [EPR16898] (Phycoerythrin) (ab211709)
- Anti-PKC antibody [EPR16898] (Alexa Fluor® 568) (ab223446)
- Anti-PKC antibody [EPR16898] - BSA and Azide free (ab250108)
Our Abpromise guarantee covers the use of ab205791 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/5000. Detects a band of approximately 80 kDa (predicted molecular weight: 77 kDa).|
FunctionCalcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in positive and negative regulation of cell proliferation, apoptosis, differentiation, migration and adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, platelet function and inflammation, by directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP. Involved in cell proliferation and cell growth arrest by positive and negative regulation of the cell cycle. Can promote cell growth by phosphorylating and activating RAF1, which mediates the activation of the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which facilitates active cyclin-dependent kinase (CDK) complex formation in glioma cells. In intestinal cells stimulated by the phorbol ester PMA, can trigger a cell cycle arrest program which is associated with the accumulation of the hyper-phosphorylated growth-suppressive form of RB1 and induction of the CDK inhibitors CDKN1A and CDKN1B. Exhibits anti-apoptotic function in glioma cells and protects them from apoptosis by suppressing the p53/TP53-mediated activation of IGFBP3, and in leukemia cells mediates anti-apoptotic action by phosphorylating BCL2. During macrophage differentiation induced by macrophage colony-stimulating factor (CSF1), is translocated to the nucleus and is associated with macrophage development. After wounding, translocates from focal contacts to lamellipodia and participates in the modulation of desmosomal adhesion. Plays a role in cell motility by phosphorylating CSPG4, which induces association of CSPG4 with extensive lamellipodia at the cell periphery and polarization of the cell accompanied by increases in cell motility. Is highly expressed in a number of cancer cells where it can act as a tumor promoter and is implicated in malignant phenotypes of several tumors such as gliomas and breast cancers. Negatively regulates myocardial contractility and positively regulates angiogenesis, platelet aggregation and thrombus formation in arteries. Mediates hypertrophic growth of neonatal cardiomyocytes, in part through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA treatment, is required to induce cardiomyocyte hypertrophy up to heart failure and death, by increasing protein synthesis, protein-DNA ratio and cell surface area. Regulates cardiomyocyte function by phosphorylating cardiac troponin T (TNNT2/CTNT), which induces significant reduction in actomyosin ATPase activity, myofilament calcium sensitivity and myocardial contractility. In angiogenesis, is required for full endothelial cell migration, adhesion to vitronectin (VTN), and vascular endothelial growth factor A (VEGFA)-dependent regulation of kinase activation and vascular tube formation. Involved in the stabilization of VEGFA mRNA at post-transcriptional level and mediates VEGFA-induced cell proliferation. In the regulation of calcium-induced platelet aggregation, mediates signals from the CD36/GP4 receptor for granule release, and activates the integrin heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion. During response to lipopolysaccharides (LPS), may regulate selective LPS-induced macrophage functions involved in host defense and inflammation. But in some inflammatory responses, may negatively regulate NF-kappa-B-induced genes, through IL1A-dependent induction of NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which modulates EIF4G1 binding to MKNK1 and may be involved in the regulation of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of KIT activity. Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription.
Sequence similaritiesBelongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. PKC subfamily.
Contains 1 AGC-kinase C-terminal domain.
Contains 1 C2 domain.
Contains 2 phorbol-ester/DAG-type zinc fingers.
Contains 1 protein kinase domain.
Cellular localizationCytoplasm. Cell membrane. Mitochondrion membrane. Nucleus.
- Information by UniProt
FormSpecific for both beta 1 and 2 isoforms
- AAG6 antibody
- Aging associated gene 6 antibody
- KPCA_HUMAN antibody
All lanes : Anti-PKC alpha + beta + gamma antibody [EPR16898] (HRP) (ab205791) at 1/5000 dilution
Lane 1 : Brain (Human) Tissue Lysate - fetal normal tissue at 20 µg
Lane 2 : Brain (Rat) Tissue Lysate at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 77 kDa
Observed band size: 80 kDa why is the actual band size different from the predicted?
Exposure time: 4 minutes
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab205791 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab205791 has not yet been referenced specifically in any publications.